(Updated - February 22, 2021 6:59 AM EST)

Benchmark analyst Aydin Huseynov downgraded Nektar Therapeutics (NASDAQ: NKTR) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE